



Bausch & Lomb U.K. Limited

**Disclosure Report For Transfers of Value For Patient Organisations in 2023
Together with Supporting Methodological Note**

Disclosure Report For Transfers of Value For Patient Organisations in 2023

Patient Organisations UK Disclosure Report 2023											
Patient Organisation Name	Country	Types of the Support or Services Provided							Optional Indication of Patient Organisation's Total Income and/or the Company's Support as a Percentage	Description of Services or Support	Total Amount
		Financial Support			Non-financial Support	Contracted Services (Fees and expenses should be disclosed)		Non-monetary Benefit for PO ²			
		Grants	Sponsorship of Meetings	Other Sponsorships	Donations	Fees	Out of pocket/expenses				
Glaucoma UK	UK		£9,000							Sponsorship of 2023 UKEGS Conference	£9,000

Methodological Note

1. Introduction

- 1.1 Bausch & Lomb U.K. Limited (**Bausch + Lomb**), a subsidiary of Bausch + Lomb Corporation, is a member of the national Association of the European Federation of Pharmaceutical Industries and Associations (EFPIA) in the United Kingdom, the Association of the British Pharmaceutical Industry (**ABPI**). As a member, Bausch + Lomb is obliged to comply with the ABPI Codes of Conduct, including, but not limited to, the ABPI Code on Disclosure of Transfers of Value from Pharmaceutical Companies to Patient Organisations.
- 1.2 This Methodological Note has been created by Bausch + Lomb to provide supporting information about the above Patient Organisation Disclosure Report and presents how the transfers of value are categorized and in what format they are disclosed.
- 1.3 Bausch + Lomb discloses the transfer of value related to prescription-only medicines.

2. Terminology and Definitions

- 2.1 **PO/PAG** – Patient Organisation/Patient Advocacy Group. A non-for-profit legal person/entity (including the umbrella organisation to which it belongs), mainly composed of patients and/or caregivers, that represents and/or supports the needs of patients and/or caregivers and whose business address, place of incorporation or primary place of operation is in Europe
- 2.2 **Transfer of Value (ToV)** means a direct or indirect transfer of value, whether in cash, in kind or otherwise, in connection with the development or sale of medicines for human use. A direct transfer of value is one made directly by a company for the benefit of a recipient. An indirect transfer of value is one made by a third party on behalf of a company for the benefit of a recipient where the identity of the company is known to, or can be identified by, the recipient.
- 2.3 The following table defines what transfers of value to be reported in which EFPIA category.

Category	Example Activities
Financial support	<ul style="list-style-type: none"> • Charitable contributions • Educational grants • Sponsoring of speakers/faculty which by nature of purpose and funding are classified under educational grants • Placement of a brand logo in a conference program or invitation communication in exchange for supporting the program • Funding an event in return for a display booth and/or advertising space • Other advertisement space (in paper, electronic or other format) • Any other activity qualified as “Corporate/Commercial Sponsorship” under Bausch + Lomb’s applicable policies
Non-financial support	<ul style="list-style-type: none"> • In-kind donations for example, colleague time, product, or equipment
Contracted Services & Related Expenses	<ul style="list-style-type: none"> • speaking at meetings • assistance with training • writing articles and/or publications • participating in advisory boards • advising on the design etc of clinical trials • participating in market research where such participation involves • remuneration and/or travel • Travel (e.g. flight, train, taxi, car hires, tolls, mileage reimbursement, parking) and Accommodation

2.4 There were no reportable Non-financial support or Contracted Services & Related Expenses activity for this reporting period.

3. Scope of the Transfers of Value Disclosure

3.1 The Transfers of Value disclosed in this Disclosure Report covers all ToVs related to prescription-only medicines in the calendar year 2023, to the best of our knowledge, made by Bausch + Lomb and its affiliates to PO/PAGs in the United Kingdom.

3.2 **Timing of Transfers of Value:** In this Disclosure Report, Bausch + Lomb discloses the amounts of value transferred by type of ToVs during the full calendar year 2023 (i.e., 1 January 2023 to 31 December 2023). ToVs are disclosed based on the date the payment has been recorded in our internal accounting system.

3.3 Means of identification of payments and Transfers of Value:

3.3.1 **Direct Transfers of Value:** Payments from Bausch + Lomb made directly to PO/PAGs can only be made via Purchase Order or Payment Request. All such payments have been examined and considered for disclosure.

3.3.2 **Indirect Transfers of Value:** Indirect Transfers of Value to PO/PAGs which have been paid by Bausch + Lomb to third parties such as hotels or travel companies have been identified and included in our disclosure. There have been no such ToVs identified for this reporting period.

3.3.3 **Cross border Transfers of Value:** This POs Disclosure Report includes ToVs to PO/PAGs that are resident in the United Kingdom. This includes all ToVs (direct and indirect) made by any Bausch + Lomb affiliate. Bausch + Lomb works with its affiliates to gather the data to identify and disclose ToVs made by Bausch + Lomb affiliates, if any. There have been no such ToVs identified for this reporting period.

4. Finance Related Matters

4.1 **VAT:** All sums exclude any VAT.

4.2 **Currency:** All Sums are reported in British Pounds (GBP). All sums paid to or on behalf PO/PAGs for this reporting period were in GBP.

4.3 **Multi-year contracts:** It is Bausch + Lomb's policy to only enter into contracts, subject to ToV, for a maximum of one-year term. Where contracts are valid for more than one year or the term crosses over two calendar years, each individual ToV is captured and disclosed in the corresponding reporting period.